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Abstract 
 
Bioactive glasses were invented 45 years ago and have been in clinical use since the 1980s in 
otology, orthopaedics and dentistry. Initially born as bioactive materials to fill bone defects, 
bioactive glasses expanded their biomedical suitability towards a broad spectrum of tissue 
engineering and therapeutic applications, and research evolution seems to witness that their 
potential is far from being fully exploited. Classical applications of bioactive glasses involve bone 
filling materials and dental implants; however, the fascinating question to be answered in the next 
few years is: how can bioactive glasses be useful in soft tissue regeneration and to treat diseases, 
such as tumours, that may affect internal organs? This review paper focuses on research that 
demonstrates the suitability of bioactive glasses in contact with tissues outside the skeletal system, 
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including muscle and nerve tissue regeneration, treatment of diseases affecting sense organs (eye 
and ear), embolization of neoplastic tissues, cancer radiotherapy via injectable microspheres, and 
wound dressing. A prospect for future research is also provided, highlighting the potential 
associated to targeted therapy via local ion release, angiogenesis stimulation and in situ drug 
release, as well as the promise of biofabrication for the development of bioactive glass-containing 
composite constructs for organ regeneration.  
 
Keywords: Bioglass; Composites; Angiogenesis; Antibacterial properties; Cancer treatment. 
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Highlights 
 
● Bioglasses (BG) can be successfully used in contact with tissues outside the skeleton 
● Ion release from BG can be exploited to induce angiogenesis and antibacterial effect 
● Biofabrication can allow smart BG/polymer/cells constructs to be tailored 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
1. Introduction 
 
The idea of replacing damaged body parts in humans by implanting biological or artificial materials 
dates back to prehistory and there is evidence that, later, ancient Egyptian physicians systematically 
designed wooden prostheses (aesthetic foot and hand fingers) to help their ailing patients [1]. In the 
past, the research for implantable biomaterials was primarily addressed to as inert as possible 
materials that did not interact with biological environment; this concept was revolutionized with the 
invention of the first bioactive glass, currently marketed under the name of 45S5 Bioglass®, by 
Hench and co-workers in the late 1960s [2]. Bioactive glasses are, formally, non-crystalline 
ceramics that are able to bond to living tissues (primarily bone) and to stimulate new tissue growth 
while dissolving over time: these properties make them valuable candidate materials for tissue 
engineering applications. Weinstein et al. [3] showed that the strength of the interfacial bond 
between Bioglass® and patient’s bone was equal to or greater than the strength of the host bone. 
Bioglass® particulate has been in clinical use since 1993 under the commercial name of Perioglas®, 
used to fill periodontal bone defects, and more recently as NovaBone® (porous granules, injectable 
pastes, shaped morsels), used for orthopaedic and dental applications. Bioglass® has also been 
applied clinically in middle ear surgery and in one of the first prototypes of cochlear implants to 
anchor the device through the patient’s temporal bone [4].  
Since the initial discovery of 45S5 Bioglass®, many other glass formulations and types have been 
found suitable for biomedical applications [5-7]. From a compositional viewpoint, bioactive glasses 
can be basically divided into three groups, depending on the representative former oxide present in 
the formulation, i.e. SiO2-based (silicate), B2O3-based (borate) and P2O5-based (phosphate) systems. 
The first group comprises a wide range of glass formulations, including 45S5 Bioglass® (46.1SiO2-
24.4Na2O-26.9CaO-2.6P2O5 mol.%); borate glasses are characterized by higher reactivity than 
silicate materials, which results in faster bioactive kinetics [8]; phosphate glasses are resorbable 
materials and their dissolution rate can be tuned according to their oxide composition [9].  
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In addition to SiO2, B2O3 and P2O5, various amounts of other oxides may be incorporated in glass 
composition to impart peculiar properties to the material; for instance, CaO, K2O, Na2O and MgO 
are useful to adjust the surface reactivity in biological environment; ZnO, CuO and Ag2O allow the 
release of proper ions with antibacterial properties; Al2O3 is helpful to strengthen the mechanical 
properties [10]. It should be underlined that even a small variation in glass composition can deeply 
modify the features of the material. 
Bioactive glasses are commonly produced by melting-quenching routes or sol-gel technique. Cast 
glasses can be poured into moulds in order to produce rods, bars or, in general, components of 
various size and shape (e.g. prosthetic middle ear ossicles) [4]. If produced in form of powder, glass 
can be used as starting material to fabricate tissue engineering three-dimensional (3-D) porous 
scaffolds [7]. Glasses with a mesoporous texture can be produced by wet synthesis for possible use 
as local drug release vehicles [11,12]. Furthermore, these glasses can be drawn or electrospun to 
obtain micro- or nano-sized fibres [13,14]. 
Glass conversion into a partially crystalline material can be achieved by applying appropriate heat 
treatments (e.g. sintering); usually, the resulting glass-ceramics exhibit superior mechanical 
properties but lower reactivity in biological environment with respect to parent glasses. 
Until the early 1980s it was believed that only calcified tissues could form a bond to bioactive 
materials. Wilson et al. [15] first showed that soft connective tissues could also bond to 45S5 
Bioglass® if the interface was immobile. Some glass-ceramics belonging to the family called 
Ceravital® (SiO2-P2O5-CaO-MgO-Na2O-K2O system) could be also incorporated into connective 
tissues being surrounded by a soft collagenous fibrous membrane with no adverse reaction [16]. 
Wilson and Noletti [17] assessed the compositional dependence of the bonding of SiO2-CaO-Na2O-
P2O5 bioactive glasses to connective tissues, demonstrating that the material can bond to bone but 
not to soft tissues when the glass composition exceeds 52 wt.% of SiO2. This set of data provided 
the basis for clinical use of Bioglass® in middle ear ossicles replacement, where an implant able to 
bond both to bone and to tympanic membrane was desirable; since 1985, when this first Bioglass® 
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device was approved for clinical use, the spectrum of medical applications of bioactive glasses 
expanded dramatically going well beyond small bone replacement (Fig. 1). In perfect agreement 
with an impressive sentence by Prof. Hench, who wished that “creative studies of novel glasses and 
glass-ceramics are needed now more than ever to cope with the problems of a world that has finite 
resources but infinite desires” [18], today bioactive glasses are also proposed for a wide range of 
non-osseous tissue engineering applications that seemed impossible when research began. In this 
regard, emerging fields of research for bioactive glasses include neuromuscular repair (fibrous 
constructs for muscle and nerve regeneration), artificial cornea, orbital implants, epithelial and 
cardiac tissue engineering, treatment of gastric ulcers and non-osseous cancer therapy. A recent 
review paper has covered the applications of bioactive glasses (and their composites with 
biopolymers) in the field of soft tissue engineering, highlighting their potential in cardiac, lung and 
gastrointestinal tissue regeneration approaches [19]. In the present work, the clinical and 
experimental applications of bioactive glasses for the treatment of various diseases outside the 
skeletal system, excluding those already discussed by Miguez-Pacheco et al. [19], are 
systematically reviewed (Table 1). Future research directions are also explored and outlined in the 
light of the recent findings in tissue engineering and biomaterials processing technology. 
 
2. Wound healing: emphasis on the effects of ion dissolution products from bioactive glasses 
 
Wound healing represents a major challenge in medicine and is commonly associated to a number 
of clinical scenarios including skin regeneration, chronic wounds (e.g. non-healing diabetic ulcers), 
damage to mucosae and surgical sutures.  
The skin plays an important role in the prevention of infections from pathogens and at the same 
time keeping the homeostasis of the body. Once a trauma is suffered, the damaged skin should be 
immediately covered with a dressing able to maintain a moderately moist environment for 
regeneration of the skin, prevent infection, alleviate pain and remove excessive exudates. In an 
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interesting animal study, Gillette et al. [20] determined the effects of intraincisional bioactive glass 
particulate on the healing of sutured full-thickness skin wounds in dogs. The presence of glass 
particulate in soft tissues did not cause a gross inflammatory reaction but induced an increase in 
histologic signs of inflammation, which decreased with time; furthermore, subcutaneous breaking 
strength at 5 days was significantly higher in glass-treated wounds than in control wounds, which 
indicated that bioactive glass could be beneficial in treating wounds in which early healing strength 
is needed. 
The potential of some metallic cations to act as antibacterial agents in the context of wound healing 
has been widely studied as an alternative to traditional antibiotic treatments which may be followed 
by bacterial resistance. In this regard, bioactive glasses are a valuable resource as they can be doped 
with various metal oxides to provide a smart strategy for the controlled delivery of therapeutic ions 
in situ [21]. Several studies investigated the incorporation of gallium (Ga), silver (Ag) and copper 
(Cu) in silicate and phosphate glasses to prevent infections in wound dressing. It was reported that a 
concentration as low as 1 mol.% of Ga2O3 in a phosphate glass was adequate to impart a potent 
antibacterial effect due to the sustained release of Ga3+ ions [22,23]. Silver has been shown to 
induce epidermal repair in sterile skin wounds in rats by reducing the inflammatory and granulation 
tissue phases of healing [24]; released silver ions also exhibited bactericidal action as they damaged 
bacterial RNA and DNA, hence inhibiting replication [25]. It was reported that incorporation of 3 
wt.% of Ag2O imparted antimicrobial properties to a silicate glass without compromising the 
material bioactivity [26,27]. Wren et al. [28] described antibacterial (using Staphylococcus 
epidermidis and Escherichia coli) and antifungal (using Candida albicans) effects in vitro for 
silver-coated glass particles in the 42SiO2-15CaO-23Na2O-20ZnO (mol.%) system prepared by 
dipping the melt-derived particles in AgNO3. 
These concepts have been applied to surgical sutures that, incorporating a bioactive and 
antibacterial phase, can result in multifunctional composite materials with a wide range of 
applications in wound healing. Blaker et al. [29] developed novel polymer-based sutures coated 
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with silver-doped bioactive glass powder by slurry dipping method (Fig. 2). Boccaccini et al. [30] 
noted that Bioglass®-coated Vycril® sutures, produced by this method, exhibited a decrease in 
tensile strength compared to uncoated ones (385 vs. 467 MPa): the possible explanations were 
associated to mechanical damage of the suture surfaces by the hard glass particles upon coating 
preparation [31] and/or the possible infiltration of glass particles into the voids of the braided 
structure of the suture. 
Pratten et al. [32] carried out in vitro experiments using Staphylococcus epidermidis to investigate 
the antimicrobial activity of commercial Mersilk® sutures coated with 45S5 Bioglass® powder and a 
sol-gel Ag-doped glass (60SiO2-34CaO-4P2O5-2Ag2O mol.%): under batch conditions of up to 180 
min, Ag-doped sutures showed a significantly greater effect in limiting bacterial attachment 
compared to Bioglass®-coated and uncoated sutures. The research group coordinated by Prof. 
Jonathan Knowles extensively investigated the effect of Ag-doped phosphate glasses on bacterial 
biofilm formation and growth for Staphylococcus aureus, Escherichia coli and Pseudomonas 
aeruginosa, as well as how the rate of Ag+ ion release can affect the bactericidal effect [33-36]. The 
same research group also studied the antibacterial effect of Cu-doped phosphate glasses against 
Streptococcus sanguis for potential wound healing applications [37] and developed P2O5-CaO-
Na2O glass fibres doped with up to 10 mol.% of CuO [38]: it was found an increase of Cu2+ ion 
release from the glasses with higher copper content despite their lower dissolution rate, associated 
to an increasing reduction of the viable bacteria both adhering to the fibres and present in the 
culture medium.               
Interesting clinical applications of bioactive glasses for the healing of oral mucosa were reported by 
Stoor et al. [39-41], who investigated the effect of a S53P4 glass (53SiO2-23Na2O-20CaO-4P2O5 
wt.%) implants on a wide range of oral pathogens in a series of studies carried out in humans. A 
S53P4 paste exhibited a potent and relatively fast antimicrobial effect (10-60 min depending on the 
type of bacteria), inhibiting the viability of microorganisms of both supra- and sub-gingival plaque 
[39]. S53P4 granules and disks were also used as interpositional implants in 11 patients suffering 
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from nasal septum perforations [41]; successful closure was obtained in 10 cases and no implant 
extrusions1 or infections in the nasal cavity were reported after follow-up periods between 24 and 
37 months. The effect of S53P4 on Klebsiella ozaenae, a microorganism associated to atrophic 
rhinitis, was also studied both in vitro and in human patients: after follow-up periods between 19 
and 74 months, the foul odour disappeared and the mucosal membrane fully normalized [40]. 
A few commercial products containing Ag-doped phosphate glass with a polymeric adhesive for 
woundcare film dressing (Antimicrobial Arglaes® film, Antimicrobial Arglaes® Island, Medline) 
and with alginate for topical powders (Arglaes® powder, Medline) are already on the market and 
allow a prolonged control of infections. 
Angiogenesis is a key phase of wound healing which leads to the invasion of capillaries into the 
wound clots; acceleration of this process is therefore crucial and can open new perspective for the 
treatment of such injuries. In this regard, there is convincing evidence that the ion dissolution 
products released by bioactive glasses, apart from eliciting an antibacterial effect, can promote 
angiogenesis both in vitro and in vivo [42]. Day et al. [43] first showed in a series of in vitro (with 
fibroblasts) and in vivo (in rats) experiments the ability of 45S5 Bioglass® incorporated into 
poly(glycolic acid) (PGA) meshes to increase the scaffold neovascularization, which would be 
highly beneficial for the engineering of large soft tissue constructs. More recently, Lin et al. [44] 
investigated the effect of bioactive glass ointments, prepared by mixing sol-gel 58S glass (58SiO2-
33CaO-9P2O5 wt.%) micro- and nano-powders, melt-derived 45S5 Bioglass® particles and vaseline, 
on cutaneous wounds in both normal and streptozotocin-induced diabetic rats. In general, the 
analysis of wound healing rate and wound healing time showed that bioactive glasses promoted 
wound healing, stimulating the proliferation of fibroblasts and the growth of granulation tissue. The 
ointments containing glass nanoparticles healed the wounds more quickly and efficiently than those 
prepared using commercial micro-sized Bioglass® particles only. Immunohistochemical staining 
showed that the production of the growth factors VEGF and FGF2, which are beneficial to wound 
                                                          
1
 In surgery, the term “extrusion” refers to the expulsion or spontaneous removal of an implant from the host tissue. 
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healing, was also stimulated during the healing process; fibroblasts in wounds treated with bioactive 
glasses also contained rougher endoplasmic reticula and formed new capillary microvessels by the 
seventh day. Nano-sized 45S5 Bioglass® particles were also used by Rai et al. [45] in the 
fabrication of a novel poly(3-hydroxyoctanoate)-based composite scaffold for wound dressing: the 
incorporation of bioactive glass nanoparticles accelerated blood clotting time and enhanced the 
wettability, surface roughness and overall biocompatibility of the scaffold. 
Another strategy that has been recently investigated in the literature to promote angiogenesis is the 
use of cobalt-doped glasses [46], as the release of Co2+ ions is known to mimic hypoxia and, 
accordingly, the creation of hypoxia conditions is suggested to be a strategy for activating pro- and 
anti-angiogenic genes [47]. This is an interesting finding that can open new frontiers in the use of 
bioactive glasses for wound healing and skin regeneration; however, the risks associated to cobalt 
toxicity in vivo still deserves careful assessment [48]. 
In recent years, a few experimental 2-D and 3-D bioactive glass-based constructs have also been 
developed specifically for skin tissue engineering. Chen et al. [49] reported the successful synthesis 
of a nanofibrous gelatin/Bioglass® composite hydrogel by phase separation method followed by 
arming the nanofibres network with counterionic chitosan-hyaluronic acid pairs for improving the 
microstructural and thermal integrity of the scaffold in wet state. Nano-sized Bioglass®/collagen 
composite membranes have also been proposed as carriers for the sustained release of tetracycline 
hydrochloride (a wide-spectrum antibiotic) in the context of skin repair and wound dressing [50]. 
Hong et al. [51] proposed the use of ultrathin (diameter around 600 nm) mesoporous bioactive glass 
(MBG) hollow fibres (Fig. 3), fabricated by electrospinning combined with a phase-separation 
inducing agent (poly(ethylene oxide)), as a multifunctional system for skin tissue engineering 
(support to the regenerated tissue and release of appropriate drugs) when organized in the form of 3-
D macroporous membranes. Drug loading and release experiments using gentamicin sulphate 
indicated that the drug uptake and release capacity strongly depended on the fibre length; fibres 
with length above 50 µm were shown to be excellent carriers for drug delivery, whereas the 
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shortening of the fibre length reduced drug loading amounts and accelerated drug release. MBGs 
were also mixed with chitosan to produce composite films by freeze-drying for possible use as 
haemostatic membranes for skin repair [52]. 
A few experimental studies have demonstrated that bioactive glasses can be exploited to promote 
the healing of particular cases of internal wounds which affect the gastrointestinal tract. Alkaline 
ion dissolution products from bioactive glasses can have an antacid effect, thus favouring the 
healing of gastric ulcers. Interestingly, it was also reported that 45S5 Bioglass® particles can play an 
active role in the healing of superficial injury of the intestinal mucosa, promoting a process termed 
epithelial restitution. These emerging applications were reviewed elsewhere in detail [19]. 
 
3. Peripheral nerve and spinal cord repair 
 
Peripheral nerve injuries result in the partial or total loss of motor, sensory and autonomic functions 
in the area of the body concerned. They can be the consequence of a mechanical stress, exposure to 
heat, cold, irradiation, electrical injuries, burns, tumours and focal inflammation [53]. In the 
presence of serious tissue damage or a complete nerve transection, the spontaneous regeneration 
process of the peripheral nerve occurs, mainly involving the migration of Schwann cells along the 
nerve gap supporting the re-growth of axons from the proximal to the distal stump. However, the 
regeneration is often not sufficient to provide an adequate target re-innervation and a surgical 
intervention is then needed. When end-to-end suture of the nerve stumps would generate excessive 
tension, the use of a nerve autograft or allograft (nerve gaps larger than 5 cm) is the current gold 
standard, even if these options imply obvious drawbacks and rarely lead to fully satisfactory 
functional recovery [53,54]. At present, an alternative to the actual grafting techniques is 
represented by the use of a polymeric nerve guidance channel (NGC) sutured in-between the two 
nerve stumps, which protects the regenerating nerve from the scar tissue infiltration and allows the 
soluble factors accumulation to be maximized [54]. The currently commercially available devices 
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for the treatment of the peripheral nerve injuries are NGC (i.e. tubes) or membranes to wrap around 
the nerve stumps made of natural (e.g. collagen, porcine small intestinal submucosa) or synthetic 
polymers (e.g. PGA, poly(DL-lactic acid) (PDLLA)/caprolactone, poly(vinyl alcohol) (PVA) 
hydrogel) [55]. 
Glasses have also been studied for nerve regeneration in bulk, powder or fibre form, alone or in 
combination with a polymeric phase to produce a composite material. The first study that proposed 
the use of a glass for nerve regeneration was reported by Gilchrist et al. [56], who developed a 
resorbable phosphate glass tube (length 4 cm, inner diameter 4 mm) for the repair of divided facial 
nerve of sheep. The two nerve stumps were approximated inside the tube, which was then sutured to 
the epineurium through the holes at the tube extremities. Ten months after the surgical intervention, 
the glass tubes fully dissolved and all the nerves were completely regenerated with uniform 
diameter along the length. The authors concluded that the use of a soluble glass tube could be 
considered as a valuable alternative to the end-to-end suture. The glass composition was not 
reported in the paper but, in a later work published by Jeans et al. [57], the authors commented on a 
previous study regarding a glass tube used for the repair of divided facial nerve in sheep and 
referred to the glass as Corglaes® (Giltech Ltd). In the Giltech Ltd website (www.giltech.biz), 
Corglaes® is described as belonging to the Na2O-CaO-P2O5 system and can be designed with 
different compositions, dissolution rates and applications.  
Some studies by Jeans et al. [57,58] and Starrit et al. [59] reported the use of a glass fibre wrap 
made of non-woven fibres of Corglaes® used for the treatment of divided median nerves in the 
upper forelimb or facial nerves of sheep (Fig. 4a). In one of these papers, the woven fibres were 
reported to be bonded with a biodegradable polymeric solution [57]. The wrap was designed to be 
porous to allow the passage of molecules (e.g. nutrients) towards the site of repair. The two nerve 
stumps were approximated to each other and glue or sutures were used to fix the wrap in a tubular 
form around the nerve stumps. The results showed nerve repair comparable to that obtained by 
microsurgical epineurial technique and by using wrap fixed with fibrin glue [57-59] or 6/0 
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polyglactin sutures [57]. Moreover, the wraps were completely resorbed after 7 months. Based on 
these findings, the authors stated that the use of the glass fibre wrap could be an effective alternative 
to microsurgical repair, since required less skill by the surgeon without the need for sophisticated 
microsurgical equipment. 
The clinical use of NGCs is now effective for nerve defects up to about 3 cm [60] and thus the 
current scientific research is focused on the introduction of additional features and functionalities to 
the devices in order to improve their effectiveness for longer nerve defects. The main limiting 
factors for large nerve gaps seem to be the inadequate formation of fibrin cables inside the NGC, 
which is important to guide cells migration and axonal growth during regeneration, and an 
insufficient neurotrophic support [54]. One of the strategies that are currently investigated to 
improve the nerve regeneration into a NGC is the use of fibres of nanometric or micrometric 
diameter of different materials in order to support and guide the nerve tissue growth. In this context, 
fibres of different types of glass have been proposed to create a 3-D scaffold with an anisotropic 
structure, potentially carrying soluble factors, and able to sustain and direct the axonal regeneration. 
A first approach consists in using a bundle of fibres aligned inside a NGC lumen as reported by 
Bunting et al. [61], who showed that 45S5 Bioglass® fibres allowed the attachment and spreading of 
Schwann cells, which resulted to be aligned in longitudinal chains in vitro. These authors 
demonstrated that the presence of the fibres (length 0.5 cm, diameter 25 µm) inside a Silastic® 
conduit, used for the repair of a 0.5 cm gap in the sciatic nerve of adult rats, resulted in a re-
innervation comparable to that of autograft treatment and ten times greater than the one obtained in 
empty conduits or unrepaired gaps. The hypothesized mechanism was the contact guidance of the 
regenerating axons and their associated non-neuronal cells.  
Vitale-Brovarone et al. [62] studied the interaction of aligned resorbable fibres of TiO2-containing 
phosphate glass (glass code TiPS2.5, fibre diameters 25-80 µm) with glial cells (Neonatal Olfactory 
Bulb Ensheathing Cell line, NOBEC), and Dorsal Root Ganglia (DRG) neurons in vitro (Figs. 4b 
and c). It was reported that the phosphate glass fibres were permissive substrate for cell adhesion 
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and proliferation: on the aligned fibres, glial cells were well spread and enveloped the fibres while 
neurons showed bipolar morphology with neurites growing along the fibre axis direction and were 
longer than those observed on the control glass coverslip. Novajra et al. [63,64] developed 
resorbable hollow fibres of TiPS2.5 phosphate glass which could be easily filled exploiting the 
capillary action with a liquid or a hydrogel solution containing a specific molecule (e.g. a growth 
factor), that could be released from the fibres with different kinetics depending on the filling 
material. An in vitro study showed that the fibre dissolution products did not show any negative 
effect on glial cells growth and pro-/anti-apoptotic proteins expression. A NGC was produced by 
placing a glass hollow fibre bundle into a poly(ε-caprolactone) (PCL) tube. The authors concluded 
that the filling of the fibres with a solution containing a specific growth factor would ideally impart 
to the hollow PCL/glass fibre system both topographical (i.e. anisotropic structures to direct cell 
growth) and trophic cues (e.g. neurotrophic support), which seem to be the key factors to improve 
the nerve regeneration for long nerve defects. 
Another approach in the use of glass fibres to help in directing axonal regeneration is to assemble 
them within a natural polymer matrix without the use a tubular NGC. Marquardt et al. [65] 
produced fibrin scaffolds with embedded borate glass (13-93B3) fibres in a random (diameters 0.5-
10 µm) or aligned configurations (diameters 50-200 µm). They found that neurite outgrowth of 
chick DRG neurons on the scaffolds in the presence of random fibres was comparable to that of the 
pure fibrin scaffold, while it proceeded in an oriented direction on the scaffold containing aligned 
glass fibres in vitro. 
Kim et al. [66] produced 3-D scaffolds (length 3 mm) with aligned phosphate glass fibres (diameter 
15 µm) embedded into a collagen matrix and used them for the repair of transected sciatic nerves of 
rats in vivo (Fig. 4d). This study extended the previous in vitro results reported by Vitale-Brovarone 
et al. [62] demonstrating that the presence of the fibres produced a faster axonal outgrowth in the 
initial regenerating period and promoted directional extension of axons if compared to pure 
collagen scaffolds in vivo.  
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The same collagen/phosphate glass fibre constructs were also studied for the treatment of spinal 
cord injury by Joo et al. [67]. Spinal cord injury can cause serious neurological deficits and 
compromises sensory and motor functions, as well as other related problems such as bladder and 
kidney infections, cardiac and respiratory dysfunctions and bowel diseases [68]. At present, the 
treatment consists in surgical intervention of stabilization and decompression of the spinal cord, 
drug therapy and rehabilitation, which can stimulate the spinal cord plasticity. Some devices for the 
treatment of spinal cord injuries are currently under investigation in the literature, including tubular 
guide and 3-D scaffolds of naturally derived and synthetic polymers; however, effective treatments 
or scaffolds are still to be found. Joo et al. [67] obtained promising results with collagen/phosphate 
glass fibre scaffolds in vivo (scaffold diameter 1.8 mm, length 3 mm) for the treatment of divided 
rat spinal cord. The presence of the fibres resulted in an improved locomotor and bladder function 
from 8 postoperative weeks compared to pure collagen scaffolds and some axonal growth from the 
proximal and distal stump was found only in the fibre-containing scaffold. 
Micro- or nano-sized glass powder has also been recently proposed in combination with polymers 
to obtain composite devices for peripheral nerve regeneration. The presence of the glass in the 
composite material is considered to be beneficial for the improvement of the mechanical properties 
and also for the release of ions that can enhance the nerve healing process. Zhang et al. [69-72] 
investigated the use of glass powders (size < 45 µm) in the SiO2-Na2O-CaO-ZnO-CeO2 system for 
the fabrication of composite NGCs with poly(lactic-co-glycolic acid) (PLGA) and Pluronic F127. 
The authors concluded that ion release from the glass in the composite material at appropriate 
concentrations may be advantageous for peripheral nerve regeneration, particularly due to the role 
of Ca2+ in the regulation of the nerve growth cone motility and the possible participation of Zn2+ in 
neurotransmission as well as its antibacterial effect [69,70]. This composite NGC showed analogous 
mechanical properties and even superior biocompatibility in vitro compared to the commercial 
PDLLA/caprolactone NGC (Neurolac®) [71,72]. 
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Koudehi et al. [73] developed composite tubes of gelatin reinforced with nanopowders of SiO2-
CaO-P2O5-MgO glass (particle size 100 nm) and tested them in vivo for the treatment of 10 mm gap 
in the sciatic nerve of rats (Figs. 4e and f). The composite tubes resulted in the regeneration of the 
nerve, which after 3 postoperative months was comparable to a normal nerve in terms of functional 
and histological properties. 
 
4. Skeletal muscle tissue engineering and ligament repair 
 
After severe injury, such as volumetric muscle loss, the spontaneous regeneration process of 
skeletal muscle is not sufficient and the current surgical approaches show a limited success, thus 
requiring the investigation of new strategies and materials to sustain the tissue regeneration [74]. 
Few studies have been carried out with glasses for applications in muscle regeneration by the 
research group led by Prof. Jonathan Knowles. Ahmed et al. [75] found that some fibres of 
phosphate glass in the CaO-Na2O-Fe2O3-P2O5 system allowed attachment, proliferation and 
differentiation of conditionally immortal muscle precursor cell line with the formation of myotubes 
along the axis of the fibres. Shah et al. [76] found that human masseter-derived cells seeded on a 3-
D mesh construct not only attached and proliferated but also migrated along the fibres forming 
multinucleated myotubes. It was also found that 3-D aligned fibre scaffolds were able to support 
unidirectional cell alignment and caused an up-regulation of genes encoding for myogenic 
regulatory factors [77], even when the glass fibres were embedded into a collagen gel to form a 
composite scaffold [78]. 
The same research group also studied the suitability of phosphate glass (CaO-Na2O-Fe2O3-P2O5 
system) fibres bundles for the repair of bone-ligament interface by assessing the fibre solubility as 
well as the growth and functional gene expression of human cells (primary osteoblasts and 
fibroblasts) seeded onto the scaffolds and maintained in culture for up to 21 days [79]. Glass 
dissolution rate was crucial in determining the nature of cell-glass composition interaction as the 
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most soluble fibres (containing 1 mol.% of Fe2O3) failed to support the survival of cells beyond 7 
days in culture, whereas substantial growth rate took place on the least soluble fibres with 3 mol.% 
of Fe2O3. The authors suggested that these resorbable scaffolds could be used to accommodate the 
separate seeding of two cell populations in a co-culture arrangement, in order to potentially simulate 
in vitro the anatomical structure of a bone-ligament tissue interface. 
 
5. Ocular implants 
 
The importance of glass in ophthalmology is well known since ancient times as it is has been used 
for centuries to make external lenses to correct visual deficiencies. Maybe, it is less known that the 
first potentially implantable device comprising a glass element was still developed in the context of 
ocular surgery: in the late 1700s, Pellier de Quengsy suggested the use of a thin silver-rimmed 
convex glass disc as a keratoprosthesis (artificial cornea) and described in great detail the surgical 
instruments suitable for its implantation [80]. However, there is no evidence that this device was 
ever implanted and only in the mid 1800s a glass keratoprosthesis was actually inserted in rabbit 
and human eyes [81]. Since then, the use of glass as optical element in artificial corneas was 
repeatedly proposed with controversial results and, soon after the Second World War (WWII), the 
lighter and more resistant poly(methylmethacrylate) (PMMA) began to be adopted as preferable 
material.  
Historically, glass was also used for aesthetic purposes in the fabrication of artificial eyes that 
roughly filled the orbital socket after removal of the ocular globe. In the late 1800s Mules first 
described in detail the surgical placement of a hollow glass sphere into the orbital cavity of a human 
patient [82] and, in the early 1900s, orbital implants (to be inserted in the anophthalmic socket) 
began to be coupled with external ocular prostheses (to be placed between the closed conjunctival 
surface covering the orbital implant and the eyelids) to improve the aesthetic appearance of the 
patient’s face. Glass eyes, however, had to be worn with caution as they were brittle, prone to 
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implosion with acute changes in temperature and susceptible to etching from exposure to body 
secretions; after the WWII, PMMA orbital implants and ocular prostheses were introduced to 
overcome glass shortcomings and, in recent years, implantation of glass spheres has still been 
performed only in selected cases [83,84]. 
In the above-mentioned applications, the (implantable) glass element was intended to perform an 
optical or aesthetic function; on the contrary, the major added value carried by the use of bioactive 
glasses in ophthalmic surgery is the improvement of implant biointegration2, which is crucial for the 
postoperative success of the ocular device. 
 
5.1. Artificial cornea 
 
Being the silicate bioactive glasses hydrophilic, they have been proposed in a few studies for the 
manufacturing of anchorage elements, commonly referred to as “skirts”, around the optical core of 
keratoprostheses with the aim of encouraging biocolonization by corneal cells and thereby in situ 
fixation of the implant3. The first formulations to be investigated in the late 1970s belonged to the 
group of Ceravital® glass-ceramics that, however, tended to progressively dissolve after contact 
with biological fluids in vivo and, therefore, were considered unsuitable for safe prosthetic 
anchorage [85-88]. In the early 1990s, the intracorneal biocompatibility of Bioverit® I (glass-
ceramic in the SiO2-MgO-CaO-Na2O-K2O-Al2O3-F-P2O5 system, with fluorophlogopite mica and 
apatite as crystalline phases) and Bioverit® II (glass-ceramic in the SiO2-MgO-CaO-Na2O-K2O-
Al2O3-F-P2O5-TiO2 system with tetrasilicic mica and apatite as crystalline phases) was investigated 
in rabbit eyes; in spite of the good results achieved (the materials were incorporated into the host 
                                                          
2
 In the context of ocular surgery and referring to the two main application fields of bioactive glasses, the term 
“biointegration” denotes, distinctively, the fibrovascularization of porous orbital implants (i.e. the in-growth of viable 
vascular connective tissue which helps to hold the implant in place and to discourage bacterial colonization) and the 
anchorage of keratoprosthesis to the host corneal tissue.   
3
 The skirts around the currently-used keratoprostheses are made of inert polymers (e.g. poly(2-hydroxyethyl 
methacrylate) hydrogel in the AlphaCor device) or, in the case of the osteo-odonto-keratoprostheses, comprise 
autologous tissues from patient’s tooth and buccal mucosa. In the latter case, harvesting of autologous tissues requires 
extra-surgery and is stressful to the patient.  
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corneal tissue without immune reactions and irritations), the investigations were discontinued [89]. 
Few years later, a group of Finnish researchers deposited apatite/wollastonite (A/W) glass-ceramic 
coatings on the titanium skirt of keratoprostheses implanted in rabbits (Fig. 5a) in the attempt to 
avoid the in-growth of corneal or conjunctival epithelium into the anterior chamber of the eye, 
which may lead to infection and extrusion of the implant as well as to the development of 
retroprosthetic membrane and secondary glaucoma [90]. The results were encouraging and the A/W 
coatings were found suitable for the intended aim fastening the prosthesis to the corneal tissue 
before the epithelium grows inward, but also in this case the studies were discontinued probably due 
to the advent of polymeric porous keratoprosthetic skirts, that exhibited more appropriate physico-
mechanical properties for use in the ocular environment.  
More recently, Santos et al. [91] investigated the properties of a phosphate glass (65P2O5-15CaO-
10CaF2-10Na2O mol.%)-reinforced HA porous composite (porosity up to 50 vol.% using PVA as a 
pore former) for potential use as a keratoprosthetic skirt. Degradation studies showed that no mass 
loss was found under simulated physiologic conditions (immersion in Tris solution); on the 
contrary, a significant mass loss was observed under acidic conditions (immersion in citric acid 
solution) that mimicked an environment colonized by bacteria. The biological performance of these 
phosphate glass/HA composites was satisfactory when cultured with human corneal fibroblasts, that 
invaded the material porous network, grew and proliferate over a 14-day culture period. The mean 
pore size of 110 µm was found adequate to allow the implant to be colonized by corneal cells.  
Laattala et al. [92] proposed composite keratoprosthetic skirts (Fig. 5b) in which PMMA was mixed 
with a significant amount (40 wt.%) of bioactive glass particles (45S5 Bioglass®, S53P4, 1-98 
(53SiO2-6Na2O-22CaO-2P2O5-11K2O-5MgO-1B2O3 wt.%) and FL107 (64SiO2-10Na2O-16CaO-
2P2O5-6MgO-2B2O3 wt.%)) with the aim to promote corneal cell adhesion (which hardly occurs if 
PMMA alone is used). A decrease of compressive strength and elastic modulus after soaking in 
simulated aqueous humour was observed due to bioactive glass dissolution with an associated 
porosity increase; this behaviour was partially suppressed by the formation of an apatite layer on the 
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glass particle surface. As a short remark to this study, it is worth underlining that the progressive 
glass dissolution and the weak interfaces between glass particles and PMMA matrix (due to the lack 
of a covalent bond) are crucial concerns since the penetration of water molecules into the composite 
could eventually lead to local disintegration of the skirt and loosening of the keratoprosthesis in 
vivo.  
Huhtinen et al. [93] fabricated porous skirts using two melt-derived experimental silico-boro-
phosphate glasses (1-98 (5.9Na2O-7.1K2O-7.6MgO-23.9CaO-0.9B2O3-0.9P2O5-53.8SiO2 mol.%) 
and 28-04 (4.9Na2O-7.2K2O-9.0MgO-16.2CaO-2.6B2O3-60.1SiO2 mol.%)) that, after being 
reduced in powder, were pressed and finally sintered to produce ring-shaped structures with 
interconnected porosity. In vitro tests with human keratocytes showed that none of the porous 
bioactive glass structures induced a cytokine-driven inflammatory response and the adherent 
keratocytes exhibited a typical elongated, spindle-shaped morphology which suggested a good 
adhesive potential.  
An interesting in vivo investigation was reported by Liang et al. [94], who implanted experimental 
glass-ceramic disks (diameter 8 mm, thickness 0.5 mm, pore diameter 20-70 µm, porosity 37-62 
vol.%) in albino rabbit corneas. The implants with porosity above 50 vol.% were all extruded due to 
breakage and some clinical complications (corneal oedema with severe degrees of corneal 
neovascularization, opacity of the corneal lamella) were observed in the other cases. The chosen 
glass-ceramics were judged unsuitable as materials for keratoprostheses because of excessive 
roughness, thickness and brittleness; perhaps, an optimization of the structural design parameters 
(e.g. implant size, porosity and interconnectivity) maintaining unaltered the material formulation 
might lead to more satisfactory results in future studies. 
As a general comment, it is worth underlining that bioactive glasses for keratoprosthetic skirts 
should be primarily selected on the basis of their chemical/biological stability, as even a moderate 
dissolution of the glass over time may destabilise the prosthesis. A soluble glass could be an option 
only if incorporated in a stable backbone structure which is essential to maintain the optical core in 
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the correct position, as suggested in the study by Santos et al. [91]. In these cases, accurate 
investigations are necessary to explore the effects of the ion dissolution products from bioactive 
glasses in the ocular environment as well as the associated pH change. 
 
5.2. Orbital implants  
 
Commercial porous orbital implants used in current enucleation/evisceration procedures4 are made 
of hydroxyapatite (HA), polyethylene (PE) or alumina [95]; in the last 20 years, however, bioactive 
glasses have also been investigated as alternative materials by a few groups of researchers 
worldwide.  
In the late 1990s, Xu and co-workers [96] implanted bioactive glass-ceramic porous orbital implants 
in enucleated rabbits and observed no rejection over a 6-month postoperative follow-up; ultrasound 
examination revealed a venous-flow-like spectra in the implants after 3 months and histological 
analysis showed that around 90% of the implant pores were filled by fibrovascular tissue after 6 
months from implantation. Encouraged by these promising results, the same authors experimented 
glass-ceramic porous orbital devices in 102 human patients, declaring a success rate of 96.1% after 
a 2-year follow-up [97].  
More recently, the use of bioactive glass to fabricate orbital implants was claimed in a recent patent 
by Richter et al. [98], but no manufacturing or clinical studies have been reported yet in the 
literature on this type of implant. 
Milani Brandao et al. [99] implanted 45S5 Bioglass® and Biosilicate®-derived glass-ceramic cones 
(Fig. 6a) in 45 eviscerated rabbits, that were then sacrificed at 7, 90 and 180 days after surgery for 
histo-morphological examination. Biosilicate® is a patented bioactive glass (SiO2-CaO-Na2O-P2O5 
quaternary system) originally developed by the research group of Peitl and Zanotto in Brazil [100]. 
                                                          
4
 Evisceration involves the removal of the contents of an eyeball, with the sclera and muscle attachments left intact; 
enucleation is more radical and involves the removal of the entire globe from the orbital socket, together with the scleral 
envelope and a portion of the optic nerve, while the conjunctiva, Tenon’s capsule and extraocular muscles are usually 
spared. The latter procedure is highly recommended in the case of ocular tumours. 
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Two types of Biosilicate®-derived glass-ceramic cones were implanted in rabbits [99] depending on 
the applied thermal treatment: the heat treatment produced a calcium-sodium silicate as the 
crystalline phase of Biosilicate® I, while the nucleation of apatite was induced in Biosilicate® II. No 
cone extrusions from the ocular socket were reported; histological examinations revealed the 
formation of a pseudocapsule around the cones with an inflammatory reaction that progressively 
decreased over time. 45S5 Bioglass® and Biosilicate® I conical implants caused a milder 
inflammatory reaction and the formation of a thinner fibrous capsule with respect to Biosilicate® II 
ones; further studies will contribute to better assess the suitability of these two materials as orbital 
implants and their possible added values compared to existing solutions.  
Another interesting application involves the use of bioactive glass as a “contingency plan” to fill old 
peg5 tracts and to permit re-pegging in porous HA orbital implants, if the initial drilled tunnel was 
not perpendicular and central to the implant surface [101]. This approach has been reported in a 
study on 3 patients who had pegged HA orbital implants with related complications and, over a 2-
year period, did not respond to conservative treatment. After removal of the old peg, the hole was 
partially filled with bioactive glass and, after 2 months, 2 patients underwent successful implant re-
drilling followed by insertion of a new titanium peg, with satisfactory connection to the ocular 
prosthesis and absence of complications over a 3-year follow-up. 
In a couple of recent studies, bioactive glass-coated PE porous spheres were experimentally 
implanted in enucleated rabbits [102] and human patients [103] to investigate the effect of bioactive 
glass on the fibrovascular in-growth within the implant pore network. Interestingly, however, the 
inclusion of bioactive glass particulate did not seem to significantly promote the rate of 
fibrovascularization, and probably this was the reason why the investigations on such composite 
implants were (apparently) discontinued. 
                                                          
5
 “Pegging” is a surgical procedure that can be optionally performed after some months from orbital implant placement 
in the anophthalmic socket (primary surgery). In this procedure, a hole is drilled into the front surface of the implant 
and a polymeric or metal peg is inserted into this hole. The peg articulates with a cavity in the back surface of the 
aesthetic ocular prosthesis, thereby providing improved motility and a more “life-like” appearance to the prosthetic eye. 
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Very recently, Ye et al. [104] coated macroporous HA orbital implants with a thin layer of CuO-
containing MBG (Figs. 6b and c): the aim of this research was to combine the antibacterial effect of 
released Cu2+ ions with the drug uptake/release capacity of the mesoporous coating. Specifically, 
Cu-MBG coatings with 0-5 mol.% of CuO were prepared by direct dipping of the HA porous 
implant into the Cu-MBG sol precursor, followed by evaporation, ageing and calcination. With the 
peculiarity of releasing antibacterial Cu2+ ions as the glass degrades (viability of Staphylococcus 
aureus and Escherichia coli was inhibited) and good drug uptake/delivery ability (in this study 
ofloxacin), Cu-MBG coating could be a promising, multifunctional tool in the prevention of 
implant-related infections. Furthermore, there is an additional, perhaps even more important reason 
why this approach is so fascinating – which however was not highlighted in that research article: 
several tissue engineering studies have demonstrated that Cu2+ ions released from bioactive glasses 
induce migration and proliferation of endothelial cells during in vitro culture (angiogenic effect) 
[105,106], which could promote and accelerate fibrovascularization of porous orbital implants with 
significant increment of the postoperative success rate. 
It is worth underlining that soluble glasses can be used only in form of a coating on a non-
absorbable structure which acts as a permanent “skeleton” of the orbital implant, in order to ensure 
socket volume replacement for the patient’s lifetime without the need for subsequent surgical 
substitution. 
 
5.3. Artificial retina 
 
In spite of the enormous efforts and advances in clinical treatment of eye diseases, there is no 
established method to prevent or cure some degenerative processes in eye, such as age-related 
macular degeneration and retinitis pigmentosa. Artificial retina (also termed “bionic eye”) aims to 
substitute degenerated visual photoreceptors and neural structures for stimulating intact neural 
tissue so that a meaningful visual sensation is obtained. Subretinal implants involve the placement 
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of a Si-based microphotodiode array (MPDA) in the subretinal space: an external camera connected 
to a pair of glasses worn by the patient transmits wirelessly the electromagnetic signals to the 
implanted device, and a photovoltaic charge is then generated in each photodiode cell and 
transferred to the adjacent microelectrode for stimulation of the bipolar cells. In the late 1990s, a 
group of German researchers manufactured a MPDA on a silicon wafer using complementary 
metal-oxide semiconductor process technology [107]; after completion of electrically active 
structures, a 500-nm thick passivation layer consisting of pure SiO2 glass was applied using 
tetraethylorthosilicate (TEOS) as a precursor. In vivo animal experiments (rabbits and pigs) 
revealed a decay of the SiO2 passivation layer and pit corrosion of the underlying silicon for 
implantation periods above 6 months. In order to overcome these shortcomings, other materials 
have been experimented later to produce the stimulation microelectrodes (e.g. nanoporous TiN) as 
well as the passivation layer (polyimide, bencocyclobutene and parylene C) with better outcomes 
[108]. The subretinal implant Argus II (60 electrodes) has recently received approval for 
commercial use in Europe (2011) and USA (2013) [109]. Although the choice of pure SiO2 glass as 
a protective layer was not the most fortunate, it is an interesting example about the use of a 
biocompatible glass as a thin passivation film in a bionic device (subretinal implant); in the light of 
the latest advances in tissue engineering and bioactive glass technology, maybe in the future the 
concept of using glass in artificial retinas could be resurrected to develop new, currently unexpected 
applications also in this research field.  
 
6. Treatment of ear diseases 
 
The double ability of a subset of bioactive glasses and glass-ceramics to bond both to bone and to 
soft connective tissues has been exploited in the development of artificial middle ear small bones 
(ossicles) and cochlear implants for ear surgery. Both uses have been traditionally classified as 
special osseous applications of bioactive glasses; however, they are mentioned in the present review 
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as the function of the material is not limited to bone-bonding ability and addresses the functional 
recovery of a complex sense organ (the ear).      
In the late 1970s, glass-ceramics belonging to the Ceravital® group were introduced in middle ear 
reconstructive surgery to replace the small auditory ossicles damaged by chronic infection [110], 
which leads to problems in sound conduction from the tympanic membrane to the cochlea. Animal 
studies demonstrated that this material was well-tolerated by surrounding tissues, without inducing 
irritation or negatively affecting cochlear functions [111]. Zikk et al. [112] implanted Ceravital® 
granules in the middle ear of guinea pigs (Fig. 7a) and reported a temporary hearing loss in the early 
postoperative period, which solved spontaneously around the 20th postoperative day when the 
auditory response returned to pre-surgical levels. This problem was purely conductive and due to 
surgical manipulation of the middle ear as well as to Ceravital®-induced biochemical reaction, 
which interfered temporarily with the middle ear conductive system (formation of a surface silica 
gel layer followed by collagen fibres formation and tight interfacial bonding between the granules 
and the surgical bed). Generally good long-term outcomes of Ceravital® implants were observed in 
humans over a 8-year follow-up, although some concerns about partial resorption of the implant 
over time still linger on [113]. 
In 1985, cast 45S5 Bioglass® structures (roughly similar to truncated cones) were clinically 
approved for ear ossicles replacement. This implant, called “Bioglass® Ossicular Reconstruction 
Prosthesis”, was the first bioactive glass device cleared for marketing under the commercial name 
“MEP®” [114-116]. It is interesting to underline that survivability of MEP® is considerably longer 
compared to that of “traditional” alumina implants used for the same purpose, since the latters do 
not bond to the eardrum and, therefore, gradually erode through it and are extruded within 2-3 years 
[117]. On the contrary, Bioglass® implant forms a tight bond both with the collagen fibres of the 
tympanic membrane of the eardrum and with the remaining bone of the stapes footplate and, 
thereby, is anchored on both ends, which prevents extrusion. Sound conduction is generally 
excellent without excessive fibrous tissue growth to impair sound transmission; however, some 
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issues exist about the long-term fate of such implants. Rust et al. [118] reported that no micro-
movements at the Bioglass® implant-tissue interface occurred, thus the implant remained safely 
anchored in the correct position over a maximum follow-up of 126 months. On the contrary, 
Bahamad and Merchant [119] observed that Bioglass® ossicular implants tended to break down into 
small fragments and to be partially resorbed by a host response within the middle ear after 14 years 
from implantation (Fig. 7b). Therefore, these results warrant caution in the use of ossicular 
prostheses made of Bioglass® (and Ceravital®, too) and further long-term investigations would be 
highly desirable to achieve more definite conclusions.  
In the context of ossicular replacement, it was also proposed the use of glass ionomer cement, that 
is produced by an exothermic reaction between a CaO-Al2O3-SiO2-CaF2 glass and a polyalkenoic 
acid solution. In both animal and clinical studies, the implants were coated with a mucosal layer 
within a short time and were assessed as bio-stable and well-tolerated in the middle ear environment 
[120,121]. However, this material has been fallen in disuse for middle ear surgery due to some 
concerns about aluminium lethal intoxication after contact with brain liquor [122].     
At present, the most commonly adopted solutions for ossicle replacement still remain the use of 
autografts, inert polymers or HA/PE composite (Hapex®) implants [119]. A promise for the future 
might come from the use of Biosilicate®, that was recently assessed to be safe (in powder form) in 
the middle ear environment of guinea pigs (absence of signs of oto- and vestibular toxicity at 90 
days) [123]. Recently, some authors also pointed out the potential of Bioverit® II that, after 
implantation in the middle ear, tends to be coated with an epithelial layer exhibiting absence of 
inflammation but also minimal osteogenic response [124]; antibacterial effect against gram-negative 
bacteria was also reported as an added value [125]. In order to improve the bone-bonding ability of 
Bioverit® II, it was proposed the coating of the implant with a nanostructured silica layer and 
promising results in animal middle ear models (mice and rabbits) were reported [126,127].    
The second application of bioactive glasses for ear surgery concerns the development of cochlear 
implants for those people who are profoundly deaf due to damage to sensory hair cells in their 
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cochleas. In these patients, the implants often can enable sufficient hearing for better understanding 
of speech; although the quality of sound is different from natural hearing, with less sound 
information being received and processed by the brain (typically the sounds are perceived at much 
lower frequencies), many patients are able to hear and understand speech as well as environmental 
sounds. Essentially, a cochlear implant comprises a microphone, a speech processor that selectively 
filters sound to prioritize audible speech and a transmitter on the external part of the ear, followed 
by a receiver secured in the bone under the skin that converts the signals into electric impulses and 
sends them to an array of electrodes placed through the cochlea; finally, the impulses are sent to the 
brain through the auditory nerve system [128]. One of the first prototypes, developed in the 1980s at 
the University College London [129], was based on an array of four platinum electrodes insulated 
by medical-grade Al2O3 and anchored in the bone with a 45S5 Bioglass® sleeve. The Al2O3 
envelope provided mechanical and dielectric stability to the device, while the 45S5 Bioglass® 
connector bonded both to the bone and to the soft connective tissues as it protruded through the 
skin. This hermetic, percutaneous seal – from which the common name Bioglass®-EPI 
(extracochlear percutaneous implant) – provided mechanical stability and prevented infection from 
electrodes migration, thereby protecting the patient who had to unplug the electronics at night. In a 
recent version of the device, the design concept was essentially maintained unaltered but fixation to 
bone occurred by a titanium pedestal; 45S5 Bioglass® was no longer used due to some concerns 
about the maintenance of adequate mechanical integrity over time (Bioglass® is an intrinsically 
brittle material and, furthermore, undergoes moderate dissolution in the biological environment) 
[130]. 
 
7. Treatment of liver cancer and applications of radioactive glasses 
 
In situ irradiation of cancer-affected organs has a number of advantages in comparison to using 
external radiation sources, since the radiation is applied to a more localized area, higher doses can 
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be applied for shorter periods with lower patient’s discomfort and there is less damage to healthy 
tissue [131]. An interesting method for internal therapeutic irradiation involves the creation of an 
appropriate radioisotope by neutron bombardment in biocompatible glass beads that will be 
subsequently injected into the patient’s blood flow [132]. These microspheres must be insoluble in 
the biological fluids to avoid dissolution and migration of the radioactive material via the blood 
circulation into the body, and should be sized to lodge in the capillary bed of the organ to be treated. 
A further criterion for material selection involves the absence of unwanted elements that could 
become radioactive upon neutron bombardment.  
For the treatment of liver cancer, Day and co-workers first proposed the use of injectable Y2O3-
Al2O3-SiO2 glass microspheres (diameter of 25 µm) with as much as 50 wt.% yttrium oxide, 
characterized by high durability due to the absence of alkali ions [132-134]. Before arterial infusion, 
the glass beads were bombarded by neutrons that create 90Y, a radioisotope that is a short-half-life 
(64 h) and short-range β-rays emitter. In this way, a localized dosage of up to 15000 rad could be 
delivered, whereas a maximum of  3000 rad under external radiation can be tolerated by the patient. 
At present, radioactive glass microspheres (marketed under the commercial name of TheraSphere®) 
are clinically used for the treatment of unresectable hepatocellular carcinoma, metastatic liver 
cancer and cholangiocarcinoma at a number of clinical centres in EU countries, Canada and USA 
after receiving FDA approval in 1999. This therapy leads to a significant improvement of survival 
times and quality of life for the patients.  
A variation of this approach involves the incorporation of a radionuclide in protective insoluble 
microcapsules that will be injected into the patient’s body and subsequently removed; an example is 
the treatment of prostate cancer using 142Pr glass seeds [135].  
In situ radiotherapy using Dy2O3-Li2O-B2O3-Al2O3 glass seeds, that are neutron activated to form 
165Dy, has also been proposed recently for the treatment of arthritic joints [136]; in this case, 
injectable glass beads must be soluble in biological fluids as their long-term persistence in the 
synovial fluid would cause disease aggravation. 
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8. Embolization of uterine fibroids 
 
In recent years, embolization of vascular tumours has gained increasing attention as an important 
tool in minimally invasive surgical intervention; a typical field of application is the treatment of 
symptomatic uterine fibroids, which are benign tumours from smooth muscle tissue (leiomyomas) 
that affect about 25% of all women [137,138]. Uterine fibroid embolization (UFE) comprises the 
intentional occlusion of blood vessels with embolic materials so that blood flow is obstructed, 
thereby leading to infarction of leiomyomas and reduction of fibroid-associated pain. UFE is a safe, 
effective procedure and provides similar results to hysterectomy, but has the advantage of shorter 
recovery times, uterine preservation and maintenance of potential for future pregnancy over 
conventional surgical intervention. An ideal material for UFE should be radiopaque, which is not 
fulfilled by polymeric microspheres that are used in the current surgical practice. In order to achieve 
this requirement, Kehoe et al. [139] recently demonstrated the potential suitability of various types 
of glass microspheres (size within 45-212 µm) belonging to the SiO2-CaO-ZnO-La2O3-TiO2-MgO-
SrO-Na2O system. The same research group developed an interesting set of models to analytically 
predict the composition-density and composition-cytocompatibility relationships for these 
experimental materials, that exhibited an in vitro biocompatibility with fibroblasts generally 
equivalent or enhanced in comparison to commercially available embolic polymeric agents [140]. 
Ion release profiles of glass microspheres were also determined and no genotoxic effect was 
observed in the bacterial mutation Ames assay, which further supports the potential suitability of 
these materials as embolic agents [141].  
 
9. Summary and outlook 
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Only 45 years ago, before 45S5 Bioglass® was invented by Prof. Larry Hench and co-workers [2], 
the concept of a material that could bond to living tissues with no rejection or long-term interfacial 
problems seemed impossible. Since then, bioactive glasses transformed biomedical science and 
technology and the research still continues today with impressive results: none of the latest 
applications were forecast when the research began, evolving over the years beyond orthopaedic 
and dental implants towards new, smart applications in soft tissue engineering and organ 
regeneration [19].  
Bioactive glasses are characterized by a great versatility from the viewpoints of composition and 
manufacturing, on which researchers can act to develop ever more suitable biomaterials and 
implants for tissue repair and targeted therapy. Small changes in the bioactive glass composition 
can lead to very different physico-chemical, mechanical and biological properties (e.g. mechanical 
strength, surface reactivity, dissolution kinetics), that could be therefore properly designed and 
modulated depending on the implantation site as well as on the specific implant scope. 
In this regard, a few short remarks should be dedicated to better clarify the meaning of the term 
“bioactive”, that is commonly used to define a special set of implantable glasses. In biomaterials 
science and regenerative medicine, the term “bioactivity” refers to the ability of a biomaterial to 
perform a specific function required to generate the most appropriate beneficial cellular or tissue 
response in a specific situation. Of course, bioactivity implies biocompatibility, i.e. the ability of a 
biomaterial to perform its function without eliciting any undesirable local or systemic effect in the 
recipient [142]. Initially, bioactivity referred to materials that could bond to bone (e.g. HA), but 
45S5 Bioglass® was found to bond also to soft tissues [14] and to stimulate new bone growth 
through the release of Si and Ca ions having a genetic effect on cell functions [143]. Furthermore, 
the researches carried out over the last 30 years have demonstrated that also other ions released 
from new types of glass, the shape itself of the implant (e.g. micro-/nano-sized glass fibres) or 
intrinsic atomic properties of the material (e.g. radioactivity) are all factors that can be exploited to 
induce a particular cell or tissue response in a broad range of applications, not restricted to bone-
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bonding ability. Therefore, the word “bioactive” widely expanded its meaning and should be always 
contextualized depending on the specific application, as summarized in Table 2.   
Many studies have demonstrated that a powerful strategy to design glass-derived products able to 
elicit a desired biological response involves the introduction of therapeutic ions into the bioactive 
glass formulation; the subsequent release of these ions after exposure to a physiological 
environment could allow an antibacterial, anti-inflammatory or angiogenic effect to be obtained 
[10,105,143]. Antimicrobial properties are particularly crucial if infections are one of the primary 
cause of implant failure (for instance in wound dressing and ocular implants) and, in general, in all 
cases where cells have to compete with bacteria to colonize the implant. Angiogenesis is crucial for 
the development of regenerated tissue and could be particularly desirable in the case of wound 
healing [43,44] and porous orbital implants, in which fibrovascularization is essential to hold the 
device in place and to discourage bacterial colonization [94,144].  
The introduction of metal ions is usually economical and compatible with the typical processes used 
for bioactive glass production (e.g. high-temperature melting, sol-gel method, sintering), which on 
the contrary are often incompatible with the incorporation and stability of organic moieties and 
drugs that might be used for the same purpose. Metal oxides such as CuO, Ag2O and Fe2O3, apart 
from exerting an antibacterial effect via the release of the associated metal ions, can also modulate 
the glass solubility [9,13,79]. The use of soluble materials, however, deserves careful attention 
depending on the context of application. If used for tissue engineering purposes (e.g. for muscle or 
nerve repair), bioactive glass dissolution kinetics must be compatible with the healing rate of 
regenerated tissue; on the contrary, glasses with high chemical and biological stability should be 
selected to produce orbital implants and keratoprosthetic skirts, that must remain in situ indefinitely 
during the patient’s whole life to ensure an adequate socket volume replacement without 
undergoing degradation. Long-term integrity issues related to Bioglass® ossicular implants were 
also highlighted by Bahmad and Merchant [119], who suggested caution in using this material for 
such an application. Partial resorption over time of the Bioglass® sleeve that fixed the cochlear 
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implant to temporal bone led to its substitution with a titanium pedestal in the most recent versions 
of the device [130]. As a general indication, bioactive glasses and glass-ceramics with high 
chemical and biological stability have to be developed if their function is the safe anchorage of an 
implantable prosthetic device that must not migrate over time [145,146]. Insoluble glasses are also 
highly desirable to produce injectable radioactive microspheres for cancer treatment [134].  
Incorporation of a radiopaque phase, such as zirconia (ZrO2), in the glass formulation would allow 
better visualization of the implant under radiographic imaging and detection of problems associated 
to undesired postoperative migration [147]. Furthermore, ZrO2 could be a valuable alternative to the 
potentially toxic La2O3 [140] as a radiopaque agent in glass microspheres for uterine fibroid 
embolization.   
Bioactive glasses are attractive also from a technological viewpoint due to the relative ease of 
processing associated to their production. In the context of hard tissue repair, bioactive glasses and 
glass-ceramics are usually synthesized in the form of powder to finally produce 3-D porous 
scaffolds with different size, shapes, pore architecture and mechanical properties through a number 
of relatively easy, versatile methods such as sponge replica technique [148], sol-gel foaming [149], 
polymeric particles burning-out [150], gel-cast foaming [151] and rapid prototyping techniques 
[152]. In non-osseous applications, where adequate compliance with soft tissues is required, 
bioactive glasses are often introduced as inorganic fillers in a polymeric matrix to increase the 
mechanical properties (e.g. composite nerve guidance channels [70-73]). Other uses concern the 
production of coatings to modulate cell adhesion (e.g. titanium keratoprosthesis coated with A/W 
glass-ceramics [90]) and to impart special properties, such as an antibacterial effect (e.g. glass-
coated polymeric sutures [28] or Ag-doped phosphate glass/polymer composites in the form of film 
or topical powder for wound dressing). If glasses are processed in the form of mesoporous 
materials, they can also easily uptake specific molecules, such as anti-inflammatory drugs, to be 
released in situ postoperatively to elicit an appropriate therapeutic effect [51,104]. Incorporation of 
MBGs in soft matrices, such as injectable pastes or polymer patches, could be a valuable tool for 
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the local release of chemotherapic and antineoplastic drugs for cancer treatment [153]. Phosphate 
glasses, thanks to their low glass transition temperature, can be drawn in the form of dense, hollow 
and/or mesoporous fibres, which are very attractive for the fabrication of muscle and nerve tissue 
engineering constructs. 
Looking at the future, the development of biofabrication strategies involving the use of bioactive 
glasses could open new doors in the field of organ printing. Biofabrication can be defined as the 
production of complex biological products (including portions of implantable tissues) from raw 
materials such as living cells, molecules, extracellular matrices and biomaterials [154,155]. 
Biomaterials science, cell/developmental biology and mechanical engineering are the main 
disciplines contributing to this emerging technology, the use of which is still mainly limited – 
probably due to technological issues – to “soft materials” (polymer-cells-biomolecules constructs) 
without the incorporation of a bioceramic phase. 
Due to the need for adequate compliance with soft tissues and organs, biofabrication could be a 
valuable tool for the tailoring of smart composites comprising a soft polymeric matrix and a 
bioactive glass phase (Fig. 8) carrying special added values (e.g. improvement of the mechanical 
properties, antibacterial effect, angiogenesis stimulation or local drug delivery). Furthermore, 
biofabrication could pave the way for the simultaneous regeneration of multiple tissues by using a 
functionally graded construct which comprises different cell types, biomaterials and 
architectural/topological features. In this regard it is instructive to cite a recent work by Liverani et 
al. [156], who developed a relatively simple strategy for the production of 3-layer stratified 
scaffolds with potential application in osteochondral tissue engineering by integrating sponge 
replication, freeze-drying and electrospinning. 45S5 Bioglass® was used for the fabrication of the 
rigid bioactive substrate intended to be in contact with bone tissue, chitosan and alginate solutions 
were used to build by freeze gelation the interface between the porous glass layer and the soft 
cartilage side of the construct, and a chitosan-based electrospun nanofibrous membrane was 
selected for the upper layer of the scaffold. In this design, the intermediate layer has multiple 
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functions providing adherence between the other scaffold components and preventing delamination. 
This study could represent the starting point for the development of advanced multifunctional and 
“multi-tissue” engineering scaffolds, with the aim to concretize a not so remote dream: if today, 
describing the regenerative properties of bioactive glasses, we can rightly state “not only for bone 
and teeth” (as reviewed in this article), we do hope that, in the next few years, it will be possible to 
say “not only for one tissue at the same time”.  
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Figure legends 
 
Fig. 1. Chronology of the special applications of bioactive glasses outside the skeletal system. 
 
Fig. 2. Antibacterial sutures: Mersilk® suture (a) before and (b) after being coated with Ag-doped 
bioactive glass particles (images adapted from Blaker et al. [29] © Wiley Periodicals). 
 
Fig. 3. Ultrathin hollow MBG fibres: (a) as produced fibre; (b) fibre surface after soaking for 8 h in 
SBF (small spherical apatite structures, supposed to have a haemostatic effect, are clearly visible) 
(images adapted from Hong et al. [51] © Wiley-VCH). 
 
Fig. 4. Examples of the use of bioactive glasses for peripheral nerve regeneration: (a) wrap of non-
woven mesh of phosphate glass fibres bonded with a biodegradable polymeric solution used to treat 
the divided median nerve in the upper forelimb of sheep (image adapted from Jeans et al. [57] © 
British Association of Plastic, Reconstructive and Aesthetic Surgeons); (b) glial cells enveloping 
the glass fibres and (c) dorsal root ganglia neurons showing long neurites extended along the fibre 
axis direction (images adapted from Vitale-Brovarone et al. [62] © Elsevier); (d) SEM micrograph 
showing a section of a phosphate glass fibre/collagen 3-D scaffold for peripheral nerve repair 
(image adapted by Kim et al. [66] © Wiley); (e) and (f) composite tubes (internal diameter 1.6 mm) 
of gelatin/SiO2-CaO-P2O5-MgO glass nanopowders (size 100 nm) tested for the treatment of 10 mm 
gap in the sciatic nerve of rats (image adapted from Koudehi et al. [73] © Springer). 
 
Fig. 5. Bioactive glasses and glass-ceramics for artificial cornea: (a) histological picture of rabbit 
eye with a keratoprosthesis supported by a titanium flange coated with A/W glass-ceramic (main 
image: the small arrows point to the intact aspect of the cornea under the optical element “O”, 
whereas the large arrow points to the hole in the left half of the supporting flange; inset: there is a 
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tight contact between the A/W glass-ceramic coating and the corneal matrix tissue, while the 
corneal epithelium “e” shows no in-growth but has attached to the bioactive glass-ceramic (bgc) 
coating on the part supporting the optical element) (images adapted from Linnola et al. [90] © 
Academic Press Limited); (b) PMMA/bioactive glass composite skirt around the optical PMMA 
cylinder in an experimental keratoprosthesis (images adapted from Laattala et al. [92] © Elsevier). 
 
Fig. 6. Bioactive glasses and glass-ceramics for orbital socket surgery: (a) conical orbital implants 
(anterior diameter 10 mm, posterior diameter 3 mm, length 12 mm) made of 45S5 Bioglass® (left), 
Biosilicate® I glass-ceramic (centre) and Biosilicate® II glass-ceramic (right) (image adapted from 
Milani Brandao et al. [99]); (b,c) MBG-coated porous HA scaffolds for possible use as orbital 
implants: on the left, photograph showing the outward appearance of the HA devices with different 
MBG coating (containing 0, 2 and 5 mol.% of CuO), on the right, morphology of porous HA coated 
with 5 mol.% Cu-doped MBG (images adapted from Ye et al [104] © Springer). 
 
Fig. 7. Bioactive glasses and glass-ceramics for ossicular replacement: (a) Ceravital® granules with 
size in the 0.3-0.7 mm range (C) in the middle ear of a guinea pig (J = incudo-stapedial joint, W = 
round window) (image adapted from Zikk al. [112] © Springer-Verlag); (b) 45S5 Bioglass® 
prosthesis implanted for 14 years: the implant has become fragmented, host response consists 
predominantly of connective tissue with few scattered inflammatory cells (image adapted from 
Bahmad and Merchant [119]). 
 
Fig. 8. The concept behind biofabrication: six-step transformation of analytical anatomy (top) into 
synthetic anatomy (bottom) (images adapted from Mironov et al. [154] © IOP Publishing). 
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Tables 
 
Table 1. Overview of the use of bioactive glasses for applications in contact with soft tissues, including implantable devices for organ restoration 
and therapeutic treatments (without the use of drugs or pharmaceutical agents). 
Application Material/implant Clinical use Remarks References 
Wound healing Polymeric sutures coated with 
Ag-doped bioactive glass,  
ointments containing bioactive 
glass powders, fibrous glass or 
polymer glass composite 
constructs, composite films with 
Ag-doped glass. 
Yes Experimented in humans, dogs, rats; some 
commercial products are available. 
The ions released for bioactive glasses can 
elicit an antibacterial, antifungal and/or 
angiogenic effect, which are very beneficial 
for wound healing. 
[20-52] 
Peripheral nerve 
repair 
Phosphate glass tube, phosphate 
glass fibre wrap, glass micro-
/nano-sized fibres (also in 
hollow form) bundle, micro-
/nano-sized phosphate glass 
Clinical trials are 
ongoing 
Experimented in sheep and rats; clinical 
trials ongoing. 
Glass tubes and wraps can be an effective 
alternative to microsurgical repair of divided 
nerve; aligned glass fibres inside a NGC 
[56-66,68-73] 
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powder/polymer composite  create anisotropic structures to direct cell 
growth and to potentially release 
biologically active molecules, thereby 
stimulating nerve regeneration.  
Glass powder can improve the mechanical 
properties in a composite device and release 
ions that can enhance the nerve healing 
process. 
Spinal cord repair Phosphate glass fibres/collagen 
composite 
Not yet (few animal 
studies are available) 
Experimented in rats. [67,68] 
Muscle tissue 
engineering 
Phosphate fibres alone or 
embedded in polymer-matrix 
composite constructs. 
Not yet (in vitro 
studies with cells are 
available) 
3-D aligned fibre scaffolds were able to 
support unidirectional muscle cell alignment 
and caused an up-regulation of genes 
encoding for myogenic regulatory factors. 
[75-78] 
Ligament repair Phosphate fibres Not yet (in vitro 
studies with cells are 
available) 
The fibres solubility, that can be tuned 
acting on the F2O3 content in the glass 
composition, strongly affects the 
[79] 
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proliferation and growth of human 
osteoblasts and fibroblasts. 
The proposed application was the in vitro 
simulation of the bone-ligament interface 
using co-cultures strategies. 
Artificial cornea Porous glasses or coatings for 
the keratoprosthetic skirt; 
glass/PMMA composites 
Not yet (few animal 
studies are available) 
Generally good results; promising 
experiments in rabbits. 
[80,81,85-94] 
Orbital implants Porous glass-ceramics, glass 
fillers of old peg tracts in porous 
HA implants, glass coatings on 
pre-existing porous implants (PE 
or HA) 
Yes Encouraging results (in general). 
Restoration of damaged peg tracts in old HA 
implants was successful in humans. 
Apparently, no significant improvement in 
implant fibrovascularization was observed in 
bioactive/glass/PE composite implants with 
respect to porous PE (studies in both rabbits 
and humans).  
Cu-containing MBG coatings on porous HA 
[82-84,95-
99,101-104] 
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implants exhibited antibacterial effect 
against Staphylococcus aureus and 
Escherichia coli. 
Middle ear surgery 45S5 Bioglass® or Ceravital® 
glass-ceramic structures to 
replace middle ear ossicles 
Yes  Anchoring to both remaining stapes 
footplate bone and tympanic membrane 
(collagenous tissue).  
Commercial products: Bioglass® Ossicular 
Reconstruction Prosthesis (MEP®) and 
Ceravital® ossicular chain (prosthetic 
ossicles made of Ceravital® are currently the 
unique clinical application of this type of 
glass-ceramic material). Some issues on the 
long-term integrity of these implants are 
under investigation. 
[111-118,120-
127] 
Cochlear implants 45S5 Bioglass® sleeve anchoring 
the implant through the patient’s 
temporal bone  
Yes Simultaneous bonding to bone and soft 
tissues. 
Commercial product: Bioglass® 
[128,129] 
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Extracohclear percutaneous implant (EPI) 
(currently almost totally abandoned) 
Treatment of liver 
cancer 
Injectable glass microspheres in 
the Y2O3-Al2O3-SiO2 system 
Yes Commercial product: TheraSphere® [131-136] 
Treatment of uterine 
fibroids 
Injectable glass microspheres in 
the SiO2-CaO-ZnO-La2O3-TiO2-
MgO-SrO-Na2O system 
Not yet (only in vitro 
tests with cells are 
currently available) 
Cytocompatibility tests with  rat fibroblasts. [139-141] 
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Table 2. Bioactivity of glasses used for applications in contact with soft tissues. 
Application Effect Mechanism of action 
Wound healing, sutures Antimicrobial and antifungal action 
(e.g. inhibition of biofilm formation, 
inhibition of pathogen replication); 
angiogenic effect 
Release of antibacterial ions (e.g. Ag+. Cu2+, Ga3+) from the glass that 
interfere with bacterial RNA and DNA replication and/or cause damages 
to the bacterial cell membrane 
Skin regeneration Angiogenic action Release of ion dissolution products (e.g. Cu2+) promoting blood 
microvessels formation 
Nerve regeneration Directional growth of axons on glass 
fibres; glass fibres resorb as new tissue 
forms 
Enhanced nerve healing due to the 
release of specific ions 
Shape effect of the glass fibrous construct (glass fibres orientation directs 
the cell growth). 
Release of ions can influence the regulation of the nerve growth cone 
motility (e.g. Ca2+) and neurotransmission (e.g. Zn2+)  
Muscle tissue regeneration Directional growth of muscle cells; 
glass fibres resorb as new tissue forms 
Shape effect of the glass fibrous construct (glass fibre orientation directs 
the cell growth) 
Artificial cornea Colonization of the keratoprosthetic 
skirt by keratocytes, inhibition of 
Shape effect of the interconnected porosity, the presence of which is a 
factor that would promote per se cell colonization; the mechanisms 
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corneal epithelium in-growth in the 
anterior chamber of the eye 
associated to the effects of ions released by the glass on corneal cells have 
not yet investigated. 
Orbital implants Enhanced fibrovascularization Shape effect of the interconnected porosity, the presence of which is a 
factor that would promote per se fibrovascular in-growth and blood vessel 
access (as observed in the case of HA, PE and alumina porous spheres); 
ions released from the glasses could accelerate the fibrovascularization 
rate  
Middle ear surgery Bonding to the stapes footplate bone 
as well as to the tympanic membrane 
(which is essential for long-term 
survivability of artificial middle ear 
ossicles) 
Bioactive glasses can bond to both calcified and collagenous tissues 
Cochlear implants Bonding to bone and soft tissues Bioactive glasses can bond to both calcified and collagenous tissues 
Liver cancer Internal radiotherapy Injection of radioactive glass microspheres 
Uterine fibroid Embolization of the uterine fibroid  Vessel occlusion and infarction of the leiomyomas 
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